Who Paid My Doc
Yun Shim
Critical Care Medicine Charlottesville, VA Medical Doctor
NPI 1265575138 CMS profile 912134
Uva Hospital W, Hospital Drive, Charlottesville, VA 22908
General payments
$3,899
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$564,532
Through program year 2025, Yun Shim of Charlottesville, VA is reported in the CMS Open Payments database as having received $3,899 across 4 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $564,532 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 83rd percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,884 | 3 | |
| 2022 | General | $15 | 1 |
Beside peers
- Yun Shim
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Yun Shim were reported at $3,884. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Yun Shim | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $149 | $51–$535 | $163 |
| 2020 | $0 | $110 | $30–$325 | $114 |
| 2021 | $0 | $125 | $34–$403 | $132 |
| 2022 | $15 | $157 | $49–$582 | $149 |
| 2023 | $0 | $162 | $56–$621 | $160 |
| 2024 | $0 | $168 | $53–$634 | $164 |
| 2025 | $3,884 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
618
Drug cost
$251,970
Branded share of claims
67.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 71 | $81,241 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 57 | $37,348 | |
| Dupixent Pen Dupilumab | Brand | 11 | $36,838 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 52 | $34,740 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 23 | $24,630 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 19 | $12,138 | |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 21 | $6,061 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 17 | $5,905 | |
| Roflumilast | Generic | 40 | $4,136 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 11 | $2,332 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 32 billing codesPaid by Medicare
$33,146
Medicare patients
593
Services billed
1,279
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| COPD | 57% | |
| Arthritis | 45% | |
| Ischemic heart disease | 36% | |
| Diabetes | 30% | |
| Heart failure | 30% | |
| Depression | 28% | |
| Atrial fibrillation | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Virginia
Oksana Shlobin
Critical Care Medicine · Falls Church, VA
Matthew Williams
Critical Care Medicine · Annandale, VA
Sami Abdul Jawad
Critical Care Medicine · Falls Church, VA
Rajiv Malhotra
Critical Care Medicine · Richmond, VA
Thomas Bouder
Critical Care Medicine · Winchester, VA
Christopher King
Critical Care Medicine · Falls Church, VA
Related records
Critical Care Medicine in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.